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Introduction
Gastric cancer is the fourth most common human malignancy and the second most common cause of cancer-related death worldwide (1) . The clinical outcome of gastric cancer has gradually improved, however the prognosis of patients with advanced disease is still dismal. Gastric carcinomas in the initial stages, such as early gastric carcinomas as defined by the Japanese Gastric Cancer Research Society (2), are carcinomas that are confined to the mucosa and the submucosa that are usually endoscopically or surgically resectable and can be cured (3). However, the majority of patients with advanced gastric carcinomas, defined as carcinomas that penetrate the muscle layer or beyond found that the addition of trastuzumab to cisplatin-based chemotherapy significantly improved the overall survival of advanced gastric cancer patients with over-expressed and/or amplified ERBB2 as compared to chemotherapy alone (13). As the target of therapy with trastuzumab, the evident difference between gastric cancer and breast cancer is the intratumoral heterogeneity of ERBB2 amplification (7).
It is noteworthy that recent comprehensive genomic analyses of copy number alterations with a high-resolution single nucleotide polymorphism array (14) and oligonucleotide array comparative genomic hybridization (aCGH) (15) revealed that genes encoding receptor tyrosine kinases (RTKs), such as ERBB2, FGFR2, MET and EGFR, in addition to MYC, CCND1 and MDM2 were frequently amplified in gastric cancers. It is most likely that intratumoral heterogeneity of ERBB2 amplification is based on the common chromosomal instability where new amplification of some of these genes begets new cancer cells that are dispensable with ERBB2 amplification, or co-amplification of new genes with ERBB2 gives sister cancer cells additional or synergistic growth advantages(16).
In tumors with genetic heterogeneity, the genomic landscape, as determined by results from single gene aberration assays, is critical for personalized-medicine strategies. For example, when molecularly targeted therapy against ERBB2 is used, ERBB2-negative cancer cells, if any, may survive or exhibit overgrowth after ERBB2-positive cancer cells have been killed, as we have previously reported in a case of breast cancer (17). Thus, the semi-comprehensive analysis of therapy-related genes is mandatory. Multiplex ligation-dependent probe amplification (MLPA) is a new, high-resolution method for detecting numerous copy number variations in genomic sequences in a single reaction requiring only small amounts of DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissues (18, 19). Now a detection kit for ERBB2, EGFR, MET, MYC, CCD1 and MDM2 and one for FGFR2, which we utilized in the present study, have been commercially available.
In the present study, we sought to identify the heterogeneity of ERBB2 amplification in gastric cancers and to characterize the possible diversity of amplified oncogenes with or without ERBB2 amplification. To achieve these goals, we tested the reliability of the recently developed MLPA as a tool to semi-comprehensively detect molecular changes. Forty gastric cancers without ERBB2 amplification were selected at random from 314 differentiated-type gastric adenocarcinomas for DNA examination.
Materials and Methods

Patients
DNA from cell lines MKN7, A431, KATOIII, HSC39, and MKN45, which had previously been confirmed to have amplified ERBB2, EGFR, FGFR2, FGFR2
and MYC, and MET, respectively, were used as positive controls (23, 24).
MLPA analysis was performed by using two kits from MRC-Holland 
MLPA analysis of amplification of ERBB2
The MLPA analyses was successfully performed on all of the FFPE samples. 
Amplification of genes other than ERBB2
The results of amplification of genes other than ERBB2 were summarized in Tables 1 and 2 and representative However, their ratios were less than 2.2, and the average copy numbers of MYC were less than 7; thus, they were not included in the amplified tumors (Suppl Fig. 1 
CCND1
MLPA showed three tumors with amplification of CCND1, and amplification was confirmed in the three cases by FISH (Fig. 2F ).
Co-amplification of CCND1 and ERBB2, EGFR, and MYC were found in three tumors; however, no discernible correlation between the distributions of CCND1 and the co-amplified genes was found in these tumors.
Other genes
Amplification and gain of TOP2A was found in eight and 15 tumors, respectively. Gain of the MDM2 was found in two however they showed no amplification by FISH. The other 17 genes detectable by the two MLPA kits showed no amplification or gain.
ERBB2-non-amplified tumor
All the 40 ERBB2-negative control tumors determined by IHC showed normal peak values of ERBB2. Thus, the specificity of the MLPA was 100%. Among genes with 'amplification' or 'gain', as shown in Table 2 , there were amplifications of FGFR2 in three tumors and amplification of MYC, CDK4 (Suppl Fig. 2 ) and MDM2 (Suppl Fig. 3 ) in one tumor each by FISH.
Lymph node status
Amplified genes in the metastatic cancer cells examined by FISH are shown in Table 1 .
Discussion
In the present study, the combined analysis of IHC and FISH revealed that Supplemental Figure 1 Mean ratio of MYC to CEP8 is 1.9 (case 15).
Supplemental Figure 2
Gene amplification of CDK4 in an ERBB2-negative gastric cancer.
Supplemental Figure 3 Gene amplification of MDM2 in an ERBB2-negative gastric cancer. 
